In particular, treatment with bacterial flagellin, a TLR5 agonist25, results in potent antitumor responses in various xenograft models for colon, breast, and prostate cancer as well as a number of mouse spontaneous tumor models23,26–31. Here, TLR5 is linked to neoplasm.